Recent analyses indicate 30-45% of severe NPDR patients exhibit suboptimal outcomes following anti-VEGF-laser combination therapy, manifesting as disease progression, persistent retinal pathology, or need for unplanned interventions (6, 7). The gene discussed is VEGFA; the disease is non-proliferative diabetic retinopathy.